Curative Historical Financial Ratios

CUBT Stock

USD 0.01 0.0001 1.14%

Curative Biotechnology is presently reporting on over 84 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 267 or Invested Capital of 0.0 will help investors to properly organize and evaluate Curative Biotechnology financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Curative Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Curative Stock please use our How to Invest in Curative Biotechnology guide.

About Curative Financial Ratios Analysis

Curative BiotechnologyFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Curative Biotechnology investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Curative financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Curative Biotechnology history.

Curative Biotechnology Financial Ratios Chart

At this time, Curative Biotechnology's Days Sales Outstanding is comparatively stable compared to the past year. Average Payables is likely to gain to about 1.6 M in 2024, whereas Free Cash Flow Yield is likely to drop (0.04) in 2024.

Price To Sales Ratio Days Sales Outstanding Average Payables Ev To Sales

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Curative Biotechnology stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Curative Biotechnology sales, a figure that is much harder to manipulate than other Curative Biotechnology multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most ratios from Curative Biotechnology's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Curative Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Curative Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Curative Stock please use our How to Invest in Curative Biotechnology guide.At this time, Curative Biotechnology's Days Sales Outstanding is comparatively stable compared to the past year. Average Payables is likely to gain to about 1.6 M in 2024, whereas Free Cash Flow Yield is likely to drop (0.04) in 2024.

	2023	2024 (projected)
Inventory Turnover	0.22	0.21
ROIC	2.19	2.29

Inventory Turnover Roic

Curative Biotechnology fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		0.13	0.76	-0.45	-0.5	-0.39	0.15	0.41	0.13	0.84	-0.4	-0.11	-0.43	-0.35	0.84	0.31	0.31	0.71	-0.37	-0.27	0.59	-0.37	0.4	-0.55	-0.13	-0.44
Ptb Ratio	0.13		-0.23	0.04	0.04	0.19	-0.54	0.76	1.0	-0.29	0.19	-0.93	0.18	0.59	-0.29	-0.18	0.79	0.06	0.16	0.16	-0.32	0.15	0.3	0.22	-0.78	-0.01
Days Sales Outstanding	0.76	-0.23		-0.38	-0.51	-0.4	0.37	0.07	-0.23	0.86	-0.4	0.27	-0.69	-0.5	0.89	0.24	-0.2	0.57	-0.31	-0.19	0.7	-0.31	0.32	-0.49	0.27	-0.37
Book Value Per Share	-0.45	0.04	-0.38		0.75	0.96	-0.27	-0.21	0.04	-0.42	0.97	-0.07	0.21	0.71	-0.42	-0.26	-0.08	-0.48	-0.12	0.28	-0.37	-0.12	-0.07	0.03	-0.15	-0.21
Free Cash Flow Yield	-0.5	0.04	-0.51	0.75		0.73	-0.58	-0.23	0.04	-0.57	0.73	-0.15	0.3	0.55	-0.57	-0.02	0.1	-0.27	-0.11	0.01	-0.48	-0.11	-0.64	0.04	-0.23	-0.21
Operating Cash Flow Per Share	-0.39	0.19	-0.4	0.96	0.73		-0.33	0.01	0.19	-0.44	1.0	-0.19	0.23	0.72	-0.44	-0.13	0.08	-0.53	-0.11	0.15	-0.42	-0.11	-0.03	0.02	-0.25	-0.21
Average Payables	0.15	-0.54	0.37	-0.27	-0.58	-0.33		-0.18	-0.54	0.52	-0.34	0.65	-0.14	-0.46	0.49	-0.2	-0.65	-0.23	-0.02	0.23	0.53	-0.02	0.2	-0.35	0.58	0.03
Capex To Depreciation	0.41	0.76	0.07	-0.21	-0.23	0.01	-0.18		0.76	0.07	-0.01	-0.7	0.17	0.23	0.03	0.12	0.71	0.05	-0.16	-0.12	0.1	-0.16	0.33	-0.19	-0.68	-0.23
Pb Ratio	0.13	1.0	-0.23	0.04	0.04	0.19	-0.54	0.76		-0.29	0.19	-0.93	0.18	0.59	-0.29	-0.18	0.79	0.06	0.16	0.16	-0.32	0.15	0.3	0.22	-0.78	-0.01
Ev To Sales	0.84	-0.29	0.86	-0.42	-0.57	-0.44	0.52	0.07	-0.29		-0.45	0.34	-0.43	-0.57	0.98	0.26	-0.25	0.62	-0.35	-0.21	0.81	-0.34	0.35	-0.69	0.27	-0.37
Free Cash Flow Per Share	-0.4	0.19	-0.4	0.97	0.73	1.0	-0.34	-0.01	0.19	-0.45		-0.19	0.24	0.73	-0.45	-0.15	0.08	-0.52	-0.11	0.17	-0.42	-0.11	-0.03	0.03	-0.26	-0.21
Roic	-0.11	-0.93	0.27	-0.07	-0.15	-0.19	0.65	-0.7	-0.93	0.34	-0.19		-0.17	-0.67	0.33	0.24	-0.85	-0.13	0.12	-0.23	0.38	0.12	-0.19	-0.25	0.93	0.23
Inventory Turnover	-0.43	0.18	-0.69	0.21	0.3	0.23	-0.14	0.17	0.18	-0.43	0.24	-0.17		0.31	-0.59	-0.13	0.16	-0.32	0.18	0.11	0.01	0.18	-0.17	-0.16	-0.28	0.25
Net Income Per Share	-0.35	0.59	-0.5	0.71	0.55	0.72	-0.46	0.23	0.59	-0.57	0.73	-0.67	0.31		-0.57	-0.62	0.39	-0.35	-0.15	0.61	-0.51	-0.16	0.07	0.26	-0.7	-0.28
Days Of Inventory On Hand	0.84	-0.29	0.89	-0.42	-0.57	-0.44	0.49	0.03	-0.29	0.98	-0.45	0.33	-0.59	-0.57		0.26	-0.25	0.63	-0.35	-0.21	0.71	-0.35	0.35	-0.58	0.29	-0.39
Payables Turnover	0.31	-0.18	0.24	-0.26	-0.02	-0.13	-0.2	0.12	-0.18	0.26	-0.15	0.24	-0.13	-0.62	0.26		0.11	0.3	0.06	-1.0	0.16	0.06	-0.14	-0.25	0.26	0.12
Capex To Revenue	0.31	0.79	-0.2	-0.08	0.1	0.08	-0.65	0.71	0.79	-0.25	0.08	-0.85	0.16	0.39	-0.25	0.11		0.2	-0.07	-0.13	-0.28	-0.07	0.12	0.12	-0.78	-0.14
Cash Per Share	0.71	0.06	0.57	-0.48	-0.27	-0.53	-0.23	0.05	0.06	0.62	-0.52	-0.13	-0.32	-0.35	0.63	0.3	0.2		-0.23	-0.28	0.46	-0.23	0.13	-0.32	-0.11	-0.27
Pocfratio	-0.37	0.16	-0.31	-0.12	-0.11	-0.11	-0.02	-0.16	0.16	-0.35	-0.11	0.12	0.18	-0.15	-0.35	0.06	-0.07	-0.23		-0.09	-0.22	1.0	0.02	0.4	0.41	0.94
Interest Coverage	-0.27	0.16	-0.19	0.28	0.01	0.15	0.23	-0.12	0.16	-0.21	0.17	-0.23	0.11	0.61	-0.21	-1.0	-0.13	-0.28	-0.09		-0.13	-0.09	0.17	0.21	-0.25	-0.15
Capex To Operating Cash Flow	0.59	-0.32	0.7	-0.37	-0.48	-0.42	0.53	0.1	-0.32	0.81	-0.42	0.38	0.01	-0.51	0.71	0.16	-0.28	0.46	-0.22	-0.13		-0.22	0.23	-0.82	0.27	-0.2
Pfcf Ratio	-0.37	0.15	-0.31	-0.12	-0.11	-0.11	-0.02	-0.16	0.15	-0.34	-0.11	0.12	0.18	-0.16	-0.35	0.06	-0.07	-0.23	1.0	-0.09	-0.22		0.02	0.4	0.42	0.94
Days Payables Outstanding	0.4	0.3	0.32	-0.07	-0.64	-0.03	0.2	0.33	0.3	0.35	-0.03	-0.19	-0.17	0.07	0.35	-0.14	0.12	0.13	0.02	0.17	0.23	0.02		0.04	-0.13	0.06
Income Quality	-0.55	0.22	-0.49	0.03	0.04	0.02	-0.35	-0.19	0.22	-0.69	0.03	-0.25	-0.16	0.26	-0.58	-0.25	0.12	-0.32	0.4	0.21	-0.82	0.4	0.04		-0.06	0.46
Roe	-0.13	-0.78	0.27	-0.15	-0.23	-0.25	0.58	-0.68	-0.78	0.27	-0.26	0.93	-0.28	-0.7	0.29	0.26	-0.78	-0.11	0.41	-0.25	0.27	0.42	-0.13	-0.06		0.47
Ev To Operating Cash Flow	-0.44	-0.01	-0.37	-0.21	-0.21	-0.21	0.03	-0.23	-0.01	-0.37	-0.21	0.23	0.25	-0.28	-0.39	0.12	-0.14	-0.27	0.94	-0.15	-0.2	0.94	0.06	0.46	0.47

Click cells to compare fundamentals

Curative Biotechnology Account Relationship Matchups

Curative Biotechnology fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	(2.03)	(2.18)	(1.59)	(0.56)	(4.49)	(4.26)
Book Value Per Share	(0.001107)	(0.0138)	(0.0327)	(0.0359)	(0.004746)	(0.004983)
Free Cash Flow Yield	(2.07E-4)	(0.0227)	(0.0624)	(0.14)	(0.0355)	(0.0373)
Average Payables	466.3K	198.6K	412.37	1.7M	1.5M	1.6M
Pb Ratio	(2.03)	(2.18)	(1.59)	(0.56)	(4.49)	(4.26)
Roic	0.0145	1.18	0.32	0.28	2.19	2.29
Net Income Per Share	0.001028	(0.0143)	(0.0107)	(0.009799)	(0.008785)	(0.009225)
Payables Turnover	0.0133	54.19	9.28	0.002317	0.028	0.0266
Pocfratio	(4.8K)	(51.9)	(16.24)	(7.45)	(28.99)	(30.44)
Pfcf Ratio	(4.8K)	(43.97)	(16.03)	(7.09)	(28.17)	(29.58)
Days Payables Outstanding	27.3K	6.74	39.34	157.5K	13.1K	12.4K
Income Quality	0.005188	(4.52E-4)	0.0407	0.3	0.12	0.2
Roe	(0.93)	1.03	0.33	0.27	1.85	1.94
Ev To Operating Cash Flow	(4.8K)	(54.0)	(15.82)	(8.11)	(33.51)	(35.19)
Pe Ratio	2.19	(2.11)	(4.88)	(2.04)	(2.42)	(2.55)
Return On Tangible Assets	115.78	(2.19)	(6.26)	(12.05)	(4.93)	(4.68)
Ev To Free Cash Flow	(4.8K)	(45.74)	(15.62)	(7.72)	(32.57)	(34.2)
Earnings Yield	0.46	(0.47)	(0.2)	(0.49)	(0.41)	(0.43)
Intangibles To Total Assets	0.92	0.93	0.0617	0.65	0.55	0.49
Net Debt To E B I T D A	(0.83)	(0.0868)	0.13	(0.23)	(0.88)	(0.92)
Tangible Book Value Per Share	(0.001221)	(0.0143)	(0.0358)	(0.0387)	(0.006894)	(0.007239)
Graham Number	0.005061	0.0667	0.0885	0.089	0.0306	0.0258
Shareholders Equity Per Share	(0.001107)	(0.0138)	(0.0327)	(0.0359)	(0.004746)	(0.004983)
Debt To Equity	(0.29)	(3.49E-4)	(0.12)	(0.0522)	(0.72)	(0.68)
Graham Net Net	(0.00123)	(0.0202)	(0.0361)	(0.0394)	(0.008461)	(0.008884)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Curative Stock Analysis

When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity	Operating Cycle
Cash Conversion Cycle

Curative Historical Financial Ratios

About Curative Financial Ratios Analysis

Curative Biotechnology Financial Ratios Chart

Price To Sales Ratio

Average Payables

Ev To Sales

Curative Biotechnology fundamentals Correlations

Curative Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Curative Biotechnology fundamentals Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Curative Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Days Of Inventory On Hand	+ 0.98	Ev To Sales
Free Cash Flow Per Share	+ 0.97	Book Value Per Share
Operating Cash Flow Per Share	+ 0.96	Book Value Per Share

Interest Coverage	- 1.0	Payables Turnover
Roic	- 0.93	Pb Ratio
Roic	- 0.93	Ptb Ratio
Capex To Revenue	- 0.85	Roic
Income Quality	- 0.82	Capex To Operating Cash Flow
Roe	- 0.78	Capex To Revenue